Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3413]

Everolimus for non-functional neuroendocrine tumours

Prof James Yao - University of Texas MD Anderson Cancer Center, Houston, USA

Everolimus for non-functional neuroendocrine tumours ( Prof James Yao - University of Texas MD Anderson Cancer Center, Houston, USA )

Nivolumab improves overall survival for advanced kidney cancer

Prof Padmanee Sharma - MD Anderson Cancer Center, Houston, USA

Nivolumab improves overall survival for advanced kidney cancer ( Prof Padmanee Sharma - MD Anderson Cancer Center, Houston, USA )

METEOR trial results: Cabozantinib improves advanced kidney cancer survival

Prof Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

METEOR trial results: Cabozantinib improves advanced kidney cancer survival ( Prof Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

Atrial fibrillation in CLL patients on ibrutinib

Prof Florence Cymbalista – University of Paris, Paris, France

Atrial fibrillation in CLL patients on ibrutinib ( Prof Florence Cymbalista – University of Paris, Paris, France )

Circulating levels of tumour DNA in plasma may help monitor treatment response...

Dr Constantine Tam – Peter MacCallum Cancer Centre, Melbourne, Australia

Circulating levels of tumour DNA in plasma may help monitor treatment response and resistance in CLL ( Dr Constantine Tam – Peter MacCallum Cancer Centre, Melbourne, Australia )

Tumour specific immunotherapy in CLL

Prof Catherine Wu - Harvard Medical School, Boston, USA

Tumour specific immunotherapy in CLL ( Prof Catherine Wu - Harvard Medical School, Boston, USA )

Phase I study of duvelisib in patients with relapsed or refractory CLL

Dr Susan O’Brien – University of California, Irvine, California, USA

$Phase I study of duvelisib in patients with relapsed or refractory CLL ( Dr Susan O’Brien – University of California, Irvine, California, USA )$

Expert panel discussion: The best of iwCLL 2015

Prof John Gribben, Prof Michael Hallek, Dr Michael Keating, Prof Kanti Rai

Expert panel discussion: The best of iwCLL 2015 ( Prof John Gribben, Prof Michael Hallek, Dr Michael Keating, Prof Kanti Rai )

Targeting the NEDD8-activating enzyme to induce apoptosis in CLL cells

Dr Alexey Danilov - Oregon Health and Science University, Portland, USA

Targeting the NEDD8-activating enzyme to induce apoptosis in CLL cells ( Dr Alexey Danilov - Oregon Health and Science University, Portland, USA )

High remission rates for new CLL treatment

Prof John Seymour - Peter MacCallum Cancer Centre, Victoria, Australia

High remission rates for new CLL treatment ( Prof John Seymour - Peter MacCallum Cancer Centre, Victoria, Australia )

CLL from a patient and physician perspective

Dr Brian Koffman MD – Medical Director of the CLL Society

CLL from a patient and physician perspective ( Dr Brian Koffman MD – Medical Director of the CLL Society )

Risk of bleeding-related adverse events in ibrutinib treated CLL patients

Dr Adrian Weistner - National Heart, Lung and Blood Institute, Maryland, USA

Risk of bleeding-related adverse events in ibrutinib treated CLL patients ( Dr Adrian Weistner - National Heart, Lung and Blood Institute, Maryland, USA )

More from ecancer